Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
As the United Kingdom juggles industry concerns about the region’s waning appeal and competitiveness, Eisai is getting a lift from a production-tinged fund that the British government first unveile | As the United Kingdom juggles industry concerns about the region’s waning appeal and competitiveness, Eisai is getting a lift from a production-tinged fund that the British government first unveiled in 2024.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise

After doubling sales of its Biogen-partnered Alzheimer’s disease med Leqembi in its 2025 fiscal year, Eisai figures the crawl to…

While dealmaking and investment dollars may be flowing across biopharma once again, acute challenges tied to policy, pricing and…

As China-developed assets gain more attention from biopharma dealmakers, some industry watchers want to cur | As China-developed…

The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) and the U.S. | The program looks to support…

With China's growing dominance in the biopharma R&D sector, a collection of g | A group of over 20 global pharma leaders met with…

As AbbVie continues to capitalize on its deal for ImmunoGen with the growth of commercial antibody-drug conjugate (ADC) Elahere,…